Alzheimer’s disease (AD) is considered to be common cause of dementia worldwide1. Over time, people with Alzheimer’s disease suffer memory loss as well as the ability to concentrate. In advanced stages of the disease, there are severe complications such as dehydration, malnutrition or infectio...
Both Alzheimer’s disease (AD) genetic risk factors and indices of cognitive reserve (CR) influence risk of cognitive decline, but it remains unclear whether they interact. This study examined whether a CR index score modifies the relationship between AD
(AD) is projected to grow at a CAGR of 10.97% during the forecast period 2023 to 2028. The Alzheimer's disease (AD) Diagnostics Market is witnessing bullish growth of the market driven by factors such as the regulatory approvals for Alzheimer's disease (AD) diagnosis in the world. In...
Article Open access 06 March 2023 Introduction Alzheimer’s disease (AD), the most common cause of dementia in the elderly, is a chronic neurodegenerative disease affecting approximately 30 million people worldwide in 20151,2. Although the pathogenesis of AD remains unclear, it is thought that gen...
Alzheimer’s disease (AD) is a progressive neurogenerative disease and the most common cause of dementia, with an increasing prevalence worldwide [1]. The pathophysiological changes in AD begin years or even decades before the onset of clinical symptoms [2, 3]. The failure of many recent drug...
Alzheimer's disease (AD) is one of the most common and fatal neurodegenerative conditions in the world [1]. Over 50 million people worldwide are thought to have dementia [2]. More than 90% of all dementia cases on the globe are caused by Alzheimer’s disease (AD). AD frequently include...
conference will be comprised of sessions by world category specialists in the field ofneurology. In dementia on-stream meet 2023, international symposiums, B2B conferences, international workshops will be organized to debate the particular topics within the field of dementia and Alzheimer’s disease. ...
Shanghai, October 31, 2023-- Luye Pharma Group today announced that its exclusive new drug, Rivastigmine Twice Weekly Transdermal Patch, has been approved by China's National Medical Products Administration (NMPA), for the symptomatic treatment of mild to moderate Alzheimer's disease (AD). The ...
Statistics 6.5 million The number of Americans projected currently living with Alzheimer’s disease in 2022 7 million The number of Americans projected currently living with Bipolar disorder in 2022 9 million The number of Americans projected currently living with PTSD in 2022 21 million The number ...
Alzheimer’s disease (AD), a progressive neurodegenerative disorder, affects millions of individuals worldwide. Early and accurate diagnosis is crucial for effective treatment and management of the disease. In recent years, researchers have made significant strides in identifying biomarkers that can aid ...